United States logged 18 verified funding rounds in the week ending 21 Apr 2024, totalling ≈$690.7M. Tarsus Pharmaceuticals, Inc. anchors the week with a ≈$200.0M in Pharmaceutical Manufacturing. Software Development was the busiest sector with 3 deals.
| Country | United States |
| Deals this week | 18 |
| Total raised | ≈$690.7M |
| Top sector | Software Development (3) |
| Most common round | Seed (5) |
| Most active investor | 8VC (2 deals) |
| Sources tracked | 30 |
| # | Company | Amount | Round | Sector | Announced |
|---|---|---|---|---|---|
| 1 | Tarsus Pharmaceuticals, Inc. | $200.0M | — | Pharmaceutical Manufacturing | 19 Apr 2024 |
| 2 | Ramp Holdings, Inc. | $150.0M | series d-2 | Business Services | 16 Apr 2024 |
| 3 | Parker Web | $120.0M | debt | Web Development | 09 Nov 2024 |
| 4 | Homebase | $60.0M | Series D | Software Development | 03 Apr 2024 |
| 5 | DCM Ventures | $50.0M | Series C | Venture Capital | 18 Apr 2024 |
Key Focus Group, SnappyFingers, Summit Partners, Mural Health, Breach Security, NightVision, Silvaco Inc, PeerDB and 5 more closed rounds this week. Sign up to see amounts, round types, sectors and investor lists.
Start 7-day free trial →
Tarsus Pharmaceuticals, Inc.$200.0M · Pharmaceutical Manufacturing · United States
Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.
4 more sources tracked. Read the full press release and reporter coverage.
Sign up to read →$150.0M · series d-2 · Business Services · United States
“Ramp announces Series D-2 capital raise Products Solutions Partners Resources Customers Pricing Sign in See a demo arrow_back_ios Back Blog arrow_forward Ramp news April 16, 2024 Ramp announces Series D-2 capital raise Eric Glyman Co-founder & CEO, Ramp mail In this article Unwavering commitment to customers Growing ecosystem and impact Looking to”
Investors: Khosla Ventures, Founders Fund, Sequoia Capital, Greylock, 8VC, Thrive Capital, General Catalyst, Sands Capital, D1 Capital Partners, Lux Capital, ICONIQ Growth, Definition Capital, Contrary Capital.
| # | Investor | Deals |
|---|---|---|
| 1 | 8VC | 2 |
| 2 | Khosla Ventures | 2 |
| 3 | Notable Capital | 2 |
| 4 | Y Combinator | 2 |
| 5 | 83North | 1 |
| 6 | Arkitect Ventures | 1 |
| 7 | Asymmetry Ventures | 1 |
| 8 | Bain Capital Ventures | 1 |
| 9 | Bessemer Venture Partners | 1 |
| 10 | Contrary Capital | 1 |
Software Development accounted for 3 of 18 verified deals in United States this week. The stage mix was 6 early-stage (pre-seed to seed) against 12 Series A or later. 8VC was the most active investor, backing 2 of the week's rounds.
$120.0M · debt · Web Development · United States
1 more source tracked. Read the full press release and reporter coverage.
Sign up to read →Investors: Triple Point Capital, Jefferies.
